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Tinospora crispa (L.) Hook. f. & Thomson (Menispermaceae), found in the rainforests
or mixed deciduous forests in Asia and Africa, is used in traditional medicines to treat
numerous health conditions. This review summarizes the up-to-date reports about
the ethnobotany, phytochemistry, pharmacological activities, toxicology, and clinical
trials of the plant. It also provides critical assessment about the present knowledge
of the plant which could contribute toward improving its prospect as a source of
lead molecules for drug discovery. The plant has been used traditionally in the
treatment of jaundice, rheumatism, urinary disorders, fever, malaria, diabetes, internal
inflammation, fracture, scabies, hypertension, reducing thirst, increasing appetite, cooling
down the body temperature, and maintaining good health. Phytochemical analyses
of T. crispa revealed the presence of alkaloids, flavonoids, and flavone glycosides,
triterpenes, diterpenes and diterpene glycosides, cis clerodane-type furanoditerpenoids,
lactones, sterols, lignans, and nucleosides. Studies showed that the crude extracts and
isolated compounds of T. crispa possessed a broad range of pharmacological activities
such as anti-inflammatory, antioxidant, immunomodulatory, cytotoxic, antimalarial,
cardioprotective, and anti-diabetic activities. Most pharmacological studies were based
on crude extracts of the plant and the bioactive compounds responsible for the
bioactivities have not been well identified. Further investigations are required to transform
the experience-based claims on the use of T. crispa in traditional medicine practices into
evidence-based information. The plant extract used in pharmacological and biological
studies should be qualitatively and quantitatively analyzed based on its biomarkers. There
should be detail in vitro and in vivo studies on the mechanisms of action of the pure
bioactive compounds and more elaborate toxicity study to ensure safety of the plant for
human use. More clinical trials are encouraged to be carried out if there are sufficient
preclinical and safety data.
Keywords: Tinospora crispa, traditional uses, phytochemistry, pharmacological activities, toxicity studies, clinical
trials
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INTRODUCTION
Herbs are the sources of crude drugs that are used to treat
pathologic conditions, often chronic in nature, or to achieve or
retain a state of improved health. Several cultures have distinct
uses of plants for the treatment of various diseases (Wyk and
Wink, 2004). This traditional knowledge has been vocally passed
on through a number of generations; therefore these traditional
remedies are still in practice. This knowledge on traditional
medical practice, collected over the centuries by trial and error
using the patient as the experimental animal throughout, must
contain some material worthy of additional research. This,
consequently, calls to carry out scientific studies on such plants to
confirm the claims of community folks on their medicinal effects.
Tinospora crispa (L.) Hook. f. & Thomson is a medicinal plant
belongs to the genus Tinospora of Menispermaceae family. It is
prevalent in primary rainforests or mixed deciduous forests of
South East Asia and Africa including Thailand, Malaysia, and
Indonesia (Pathak et al., 1995). It has been used in conventional
medicine to treat numerous pathologies in Malaysia (Najib Nik
a Rahman et al., 1999), Indonesia (Dweck and Cavin, 2006),
Thailand (Kongsaktrakoon et al., 1984), and the Philippines
(Quisumbing, 1951). There was a previous review of the
secondary metabolites and biological activities of T. crispa (Koay
and Amir, 2013), however, critical assessment of the present
knowledge is needed to provide the perspectives and directions
for future research and potential applications. The purpose of this
review is to provide an updated and complete overview of the
botany, phytochemistry, traditional uses, and pharmacological
activities of T. crispa.Moreover, the present knowledge obtained
mainly from experimental studies was critically assessed to
provide evidences and justifications for local and traditional
uses of T. crispa and to propose future research prospects and
potential therapeutic uses for this plant.
VERNACULAR NAMES
T. crispa, is known as “Patawali,” “Akar Patawali,” “Seruntum,”
or “Akar Seruntum” in Malaysia (Noor et al., 1989), “Brotawali,”
“Antawali,” and “Andawali” in Indonesia (Roosita et al., 2008;
Koay and Amir, 2013), “Makabuhay” (meaning “You may live”)
in Philippines, (Quisumbing, 1951), “Boraphet” in Thailand, “Da
ye ruanjinteng” in China (Li et al., 2006), “Banndol Pech” in
Cambodia (Hout et al., 2006) “Guloncho-ban” or “Golonchi”
in Bangladesh (Rahmatullah et al., 2011), and “Lyann span Zeb
kayenn” in Martinique island (Longuefosse and Nossin, 1996).
Abbreviations: Tinospora crispa (L.) Hook. f. & Thomson, T. crispa; LPS,
lipopolysaccharide; ICAM, intracellular cell adhesion molecule; M-CSF,
macrophage colony stimulating factor; VCAM, vascular cell adhesion molecule;
MCP, Monocyte chemoattractant protein; AChE, acetylcholinesterase; MRSA,
methicillin-resistantstaphylococcus aureus; NO, nitric oxide; DPPH, 2,2-
diphenyl-1-picrylhydrazyl; FRAP, fluorescence recovery after photobleaching,
BHT, butylhydroxytoluene; ICR, institute for cancer research;; IC50, half maximal
inhibitory concentration; CYP3A4, cytochrome P450 3A4; GLUT 1, glucose
transporter 1; AMPK, adenosine monophosphate-activated protein kinase; PPAR,
peroxisome proliferator-activated receptor; BW, body weight; ALP, alkaline
phosphatase; ALT, alanine aminotransferase.
PLANT DESCRIPTION
T. crispa is an herbaceous vine which extensively grows in
tropical and subtropical regions of Southeast Asia (Pathak et al.,
1995). The old stems of T. crispa are fleshy, with prominent
blunt tubercles whereas younger stems are slightly fleshy, thin
epidermis, membranous, brownish, and glabrous. The leaves are
large, heart shaped 6–12 cm long and 7–12 cm wide. Petioles
are glabrous and 5–15 cm long. Leaf blade is slightly fleshy,
both surfaces glabrous and very delicate when dried (Figure 1).
The herb contains two or three small and yellow or greenish
yellow color flowers which are fascicled. Male inflorescences is
very slender, 5–10 cm or longer. Male flower has six green and
glabrous sepals in two whorls. Outer three are ovate (1mm) while
inner three are obovate. There are 3–6 yellow color petals and
six stamens equivalent in length to petals. Female inflorescences
are 2–6 cm long, mostly one flower per node. Female flower has
sepals and petals as in male. The fruit is 7–8mm in length.
The whole plant of T. crispa was obtained from Marang,
Kuala Terengganu, Malaysia and a voucher specimen (No.
UKMB 40178) was identified and deposited at the Herbarium
of Universiti Kebangsaan Malaysia (UKM), Bangi, Malaysia. The
collection of the plant sample did not involve endangered or
protected species.
TRADITIONAL USES
T. crispa is an ingredient in Thai folk remedies. Decoction
from the stem of T. crispa has been used as an antipyretic,
in the treatment of internal inflammations, decreasing thirst,
enhancing hunger, cooling down body temperature, and for the
maintenance of good health (Kongsaktrakoon et al., 1984; Dweck
and Cavin, 2006). The cold infusion of the seed has been used
FIGURE 1 | (A) whole plant of Tinospora crispa (B) leaves of Tinospora crispa
(C) dried stem of Tinospora crispa (D) flowers of Tinospora crispa.
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to treat intoxication caused by drugs or alcohol. An infusion
of its stem is drunk as vermifuge, a decoction of the stem is
used to wash aching eyes and syphilitic sores, the crushed leaves
are applied on wounds and made into dressing for itch. In
Indonesia (Borneo) it has been used for the treatment of diabetes,
hypertension, and backache (Dweck and Cavin, 2006). T. crispa
has been used conventionally against a wide variety of health
ailments by Yao communities of China. They used it to treat
bruises, septicemia, fever, fracture, scabies, and other tropical
ulcer-related disorders (Li et al., 2006). In Malaysia, T. crispa
is used traditionally for numerous therapeutic purposes like
diabetes, hypertension, stimulation of appetite, and protection
from mosquito bites (Gimlette and Burkill, 1930). The infusion
from the stems is used as a vermifuge. Personal communications
with local traditional medicine practitioners highlighted its
popular use as a general tonic. Moreover, it is used as an anti-
parasitic agent in both humans and domestic animals (Noor et al.,
1989). In Bangladesh, the juice of stem is used in the treatment of
intestinal disorders, jaundice, rheumatism, body pain, paralysis,
skin disease, and leprosy. The aqueous leaf extract is used to treat
flatulence, dyspepsia, diarrhea, and rheumatism by traditional
therapists in the Philippines. It is also used to prepare a poultice
with coconut oil to treat arthritis. The traditional uses of T. crispa
are summarized inTable 1 along with the parts used andmethods
of administration.
PHYTOCHEMISTRY
T. crispa comprises of a diversity of secondary metabolites. A
number of studies have been carried out on the constituents
of T. crispa, and more than 65 compounds have been isolated
and identified such as furanoditerpenes, lactones, steroids,
flavonoids, lignans, and alkaloids (Table 2). Among these
isolated compounds, clerodane-type furanoditerpenes are the
characteristic compounds of T. crispa.
Flavonoids
Till date, three flavones and three flavone glycosides have been
identified from the stem of T. crispa, namely, apeginin (1) (Lin,
2009), diosmetin (2), genkwanin (3), luteolin 4′-methyl ether 7-
glucoside (4), genkwanin 7-glucoside (5), and luteolin 4′-methyl
ether 3′-glucoside (6) (Umi Kalsom and Noor, 1995; Figure 2).
Terpenoids
A number of terpenoids (7–33), classified as triterpenoids
(7–8), and diterpenoids (9–34), have been isolated from
different parts of T. crispa. The triterpenoids, cycloeucalenol
(7) and cycloeucalenone (8) were also isolated from the stem
(Kongkathip et al., 2002). Diterpenoids and their glycosides are
the main terpenoids in T. crispa and the most common are the
clerodane-type furanoditerpenoids. Diterpenoids, tinocrispol A
(9) (Lam et al., 2012), borapetol A (10), borapetols B (11), were
isolated from the ethanol extract of T. crispa vines (Fukuda et al.,
1985, 1986; Chung, 2011; Figure 3).
Diterpenoid glycosides, 2-O-lactoylborapetoside B (12), 6′-
O-lactoylborapetoside B (13), borapetoside A (14), borapetoside
B (15), borapetoside C (16), borapetoside D (17), borapetoside
E (18), borapetoside F (19) (Martin et al., 1996), borapetoside
G (20), borapetoside H (21), rumphioside A (22), rumphioside
B (23), rumphioside C, rumphioside F, rumphioside I, syringin
(24), columbin (25), tinocrisposide A, tinocrisposide B,
tinocrisposide C, and tinocrisposide D were isolated from the
methanol extract of T. crispa (Chung, 2011; Lam et al., 2012;
Figure 3).
Choudhary et al. (2010b) also isolated nine new cis clerodane-
type furanoditerpenoids, from aerial parts of T. crispa, viz.
(3R,4R,5R,6S,8R,9S,10S,12S)-15,16-epoxy-3,4-epoxy-6-O-(β-D-
glucopyranosyl)-cleroda-3,13(16),14-trien-17,12-olid-18-oic
acid methyl ester (26), (1R,4S,5R,8S,9R,10S,12S)-15,16-epoxy-
4-O-(β-D-glucopyranosyl)-cleroda-2,13(16),14-triene-17(12),
18(1)-diolide (27), (2R,5R,6R,8R,9S,10S,12S)-15,16-epoxy-2
-hydroxy-6-O-(β-D-glucopyranosyl)-cleroda-3,13(16),14-trien-
17,12-olid-18-oic acid methyl ester (28), (5)R,6R,8S,9R,10R,12S)-
15,16-epoxy-2-oxo-6-O-(β -D-glucopyranosyl)-cleroda-3,
13(16),14-trien-17,12-olid-18-oic acid methyl ester (29),
(2R,5R,6R,8S,9S,10S,12S)-15,16-epoxy-2-hydroxy-6-O-{β -D-
glucopyranosyl-(1-6)α-D-xylopyranosyl}-cleroda-3,13(16),14-
trien-17,12-olid-18-oic acid methyl ester (30), rumphiol E
(31), (5R,6R,8S,9R,10S,12S)-15,16-epoxy-2-oxo-6-O-(β-D-
glucopyranosyl)-cleroda-3,13(16),14-trien-17,12-olid-18-oic
acid methyl ester (32), (5R,6S,9S,10S,12S)-15,16-epoxy-
2-oxo-6-O-(β-D-glucopyranosyl)-cleroda-3,7,13(16),14-
tetraen-17,12-olid-18-oic acid methyl ester (33), and
(2R,5R,6S,9S,10S,12S)-15,16-epoxy-2-hydroxy-6-O-(β-D-
glucopyranosyl)-cleroda-3,7,13(16),14-tetraen-17,12-olid-18-oic
acid methyl ester (34) (Figure 4).
Alkaloids
Alkaloids are important secondary metabolites from the
plant. To date, 21 quaternary alkaloids have been isolated
(35-57) and classified into protoberberine, furonoquinolone,
and aporphine alkaloids (Figure 5). The most common
alkaloids found in T. crispa are aporphines. These include
N-formylasimilobine 2-O-β-D-glucopyranoside (35),
N-formylasimilobine 2-O-β- D-glucopyranosyl-(1 → 2)-β-
D-glucopyranoside (tinoscorside A) (36), magnoflorine (37),
N-demethyl-N-formyldehydronornuciferine (38) (Fukuda
et al., 1983; Choudhary et al., 2010a), N-formylanonaine
(39), N-acetylanonaine (40), N-formylnornuciferine (41),
N-acetylnornuciferine (42) (Pachaly et al., 1992; Na et al.,
2005), and lysicamine (43) (Sumimoto Chemicals Co Ltd,
1982). The furquinolone alkaloids isolated from T. crispa
comprise tyramine (44), higenamine (45) (Praman et al., 2012),
N-cis-feruloyltyramine (46), N-trans-feruloyltyramine (47),
paprazine (48), and N-trans-caffeoyltyramine (49) (Naomichi
et al., 1983; Chung, 2011). The protoberberine alkaloids include
4,13-dihydroxy-2,8,9-trimethoxydibenzo[a,g]quinolizinium
(50), columbamine (51), dihydrodiscretamin (52) (Yusoff et al.,
2014), palmatine (53), jatrorrhizine (54) (Sumimoto Chemicals
Co Ltd, 1982), and berberine (55) (Bisset and Nwaiwu, 1983).
Salsolinol (56) (a tetrahydroisoquinoline) and (−)-Litcubinine
(57) (a dibenzopyrrocoline type alkaloid) were identified from
n-butanol fraction of T. crispa stem (Praman et al., 2012).
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TABLE 1 | Traditional uses of Tinospora crispa.
Country Traditional name Part used Mode of use Traditional use References
Thailand Khruea khao
ho-Boraphet
Stem
Leaves
Roots
Infusion
Decoction
Crushed leaves
Treatment of fever, cholera, diabetes, rheumatism,
and snake-bites
As a vermifuge
As a wash for sore eyes and syphilitic sores.
Treatment of wound itching and internal
inflammation
To reduce thirst and increase appetite
Kongsaktrakoon et al., 1984
Seed Cold infusion Intoxication due to drugs or alcohol Srithi et al., 2009
stem Decoction Chewing Antipyretic, appetizer, bitter tonic, stomachic, eyes
and ears problems, mucous congestion, intestinal
parasites
Gimlette and Burkill, 1930
stem Decoction Hemorrhoid Chuakul et al., 2002
Indonesia Antawali Brotowali Stems Infusion Treatment of fever and malaria
Treatment of stomachache and jaundice. To treat
fevers caused by smallpox and cholera. Murut
community traditionally uses T. crispa to treat
diabetes, hypertension, lumbago, postpartum
remedy and muscle pain
Roosita et al., 2008
Malaysia akar patawali or akar
seruntum
Whole plant boiling Kadazan-dusun community treats hypertension and
malaria by drinking boiled plant
Ahmad and Ismail, 2003
Malaysia Stem Decoction Tuberculosis Aqueous extract of T. crispa stems is
taken orally to treat diabetes mellitus
Noor et al., 1989; Mohamad
et al., 2011
Bangladesh (Guloncho-ban)
Golonchi
Stem Juice obtained from
macerated stems
Garo and Non-Garo traditional medicinal
practitioners in Bangladesh use it for the prevention
of intestinal disorders
Rahmatullah et al., 2011
Vines juice A combination of T. crispa and Saccharum
officinarum is used to treat fever
Islam et al., 2011
Leaf stem Juice The leaf and stem juice is used to treat jaundice and
rheumatism. To relieve body pain leaf and stem juice
is massaged onto the affected area twice daily for 7
days
Rahmatullah et al., 2009
Stem leaves Pills
Juice
Boiling extract
Paralysis, abdominal pain, skin disease, leprosy Kadir et al., 2014
China Da ye ruan jin teng Rattan Yao communities of China use it for fracture,
contusion, bitten by viper, carbuncle, furuncle,
septicaemia, fever, scabies, and other tropical ulcer
related disorders
Li et al., 2006
Cambodia Banndol Pech stem Fever
Rheumatism
Hout et al., 2006
Martinique island (Lyann span Zeb
kayenn)
Leaves Stem Decoction(oral) Anti diabetics Longuefosse and Nossin,
1996
Philippine Makabuhay Leaf Stem Aqueous extract Treatment of flatulence, Indigestion, diarrhea, and
rheumatism
To treat arthritis when prepared as a poultice with
coconut oil
Quisumbing, 1951
Lignans, Nucleosides, and Sterols
Lignans are group of compounds that arise from the shikimic acid
pathway. Secoisolariciresinol (58) and syringaresinol (59) are
lignans isolated from the methanol extract of T. crispa (Chung,
2011). Adenosine (60), uridine (61), and adenine (62) are the
nucleosides isolated from the n-butanol fraction of T. crispa stem
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TABLE 2 | Chemical group, part of plant studied, and chemical constituents isolated from T. crispa.
No Chemical group Part of plant References
FLAVONE AND FLAVONE GLYCOSIDES
1 Apigenin Stem Lin, 2009
2 Diosmetin (Luteolin 4′-methyl ether) Stem Umi Kalsom and Noor, 1995
3 Genkwanin Stem Umi Kalsom and Noor, 1995
4 Luteolin 4′-methyl ether 7-glucoside Stem Umi Kalsom and Noor, 1995
5 Genkwanin 7-glucoside Stem Umi Kalsom and Noor, 1995
6 Luteolin 4′-methyl ether 3′-glucoside Stem Umi Kalsom and Noor, 1995
TRITERPENE
7 Cycloeucalenol Stem Kongkathip et al., 2002
8 Cycloeucalenone Stem Kongkathip et al., 2002
DITERPENE AND DITERPENE GLUCOSIDE
9 Tinocrispol A Stem Lam et al., 2012
10 Borapetol A Whole plant Fukuda et al., 1985; Chung, 2011
11 Borapetols B Whole plant Fukuda et al., 1986; Chung, 2011
12 2-O-lactoylborapetoside B Stem Lam et al., 2012
13 6′-O-lactoylborapetoside B Stem Lam et al., 2012
14 Borapetoside A Stem Martin et al., 1996; Chung, 2011
15 Borapetoside B Stem Martin et al., 1996; Chung, 2011
16 Borapetoside C Stem Martin et al., 1996; Chung, 2011
17 Borapetoside D Stem Martin et al., 1996; Chung, 2011
18 Borapetoside E Stem Martin et al., 1996; Chung, 2011
19 Borapetoside F Stem Martin et al., 1996; Chung, 2011
20 Borapetoside G Stem Choudhary et al., 2010b
21 Borapetoside H Stem Lam et al., 2012
22 Rumphioside A Stem Chung, 2011
23 Rumphioside B Stem Chung, 2011
24 Syringin Stem Cavin et al., 1998; Chung, 2011
25 Columbin Stem Lam et al., 2012
CISCLERODANE- TYPE FURANODITERPENOIDS
26 (3R,4R,5R,6S,8R,9S,10S,12S)-15,16-Epoxy-3,4-epoxy-6-O-(β-D-glucopyranosyl)-cleroda-3,13(16),14-trien-
17,12-olid-18-oic acid methyl
ester
Areial parts Choudhary et al., 2010b
27 (1R,4S,5R,8S,9R,10S,12S)-15,16-Epoxy-4-O-(β-D-glucopyranosyl)-cleroda-2,13(16),14-triene-17(12),18(1)-
diolide
Areial parts Choudhary et al., 2010b
28 (2R,5R,6R,8R,9S,10S,12S)-15,16-Epoxy-2-hydroxy-6-O-(β-D-glucopyranosyl)-cleroda-3,13(16),14-trien-
17,12-olid-18-oic acid methyl
ester
Areial parts Choudhary et al., 2010b
29 (5R,6R,8S,9R,10R,12S)-15,16-Epoxy-2-oxo-6-O-(β-
D-glucopyranosyl)-cleroda-3,13(16),14-trien-17,12-olid-18-oic acid methyl ester
Areial parts Choudhary et al., 2010b
30 (2R,5R,6R,8S,9S,10S,12S)-15,16-Epoxy-2-hydroxy-6-O-{β-
D-glucopyranosyl-(1-6)α-D-xylopyranosyl}-cleroda-3,13(16),14-trien-17,12-olid-18-oic acid methyl ester
Areial parts Choudhary et al., 2010b
31 Rumphiol E Areial parts Choudhary et al., 2010b
32 (5R,6R,8S,9R,10S,12S)-15,16-Epoxy-2-oxo-6-O-(β-D-glucopyranosyl)-cleroda-3,13(16),14-trien-17,12-olid-
18-oic acid methyl
ester
Areial parts Choudhary et al., 2010b
33 (5R,6S,9S,10S,12S)-15,16-Epoxy-2-oxo-6-O-(β-D-glucopyranosyl)-cleroda-3,7,13(16),14-tetraen-17,12-
olid-18-oic acid methyl
ester
Areial parts Choudhary et al., 2010b
34 (2R,5R,6S,9S,10S,12S)-15,16-Epoxy-2-hydroxy-6-O-(β-D-glucopyranosyl)-cleroda-3,7,13(16),14-tetraen-
17,12-olid-18-oic acid methyl
ester
Areial parts Choudhary et al., 2010b
(Continued)
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TABLE 2 | Continued
No Chemical group Part of plant References
ALKALOIDS
35 N-formylasimilobine 2-O-β-D-glucopyranoside Stem Choudhary et al., 2010a
36 N-formylasimilobine 2-O-β-D-glucopyranosyl-(1→ 2)-β-D-glucopyranoside Stem Fukuda et al., 1983; Choudhary
et al., 2010a
37 Magnoflorine Stem Fukuda et al., 1983; Choudhary
et al., 2010a; Yusoff et al., 2014
38 N-demethyl-N-formyldehydronornuciferine Stem Choudhary et al., 2010a
39 N-formylanonaine Stem Pachaly et al., 1992; Choudhary
et al., 2010a; Yusoff et al., 2014
40 N-acetylanonaine Stem Pachaly et al., 1992; Lin, 2009
41 N-formylnornuciferine Stem Pachaly et al., 1992; Choudhary
et al., 2010a; Yusoff et al., 2014
42 N-acetylnornuciferine Stem Pachaly et al., 1992; Chung, 2011;
43 Lysicamine Stem Sumimoto Chemicals Co Ltd, 1982
44 Tyramine Stem Praman et al., 2012
45 Higenamine Stem Praman et al., 2012
46 N-cis-feruloyltyramine Stem Chung, 2011
47 N-trans-feruloyltyramine Stem Choudhary et al., 2010a; Yusoff
et al., 2014
48 Paprazine Stem Choudhary et al., 2010a
49 N-trans-caffeoyltyramine Stem Lin, 2009
50 4,13-dihydroxy-2,8,9-trimethoxydibenzo[a,g]quinolizinium Stem Yusoff et al., 2014
51 Columbamine Stem Yusoff et al., 2014
52 Dihydrodiscretamin Stem Yusoff et al., 2014
53 Palmatine Stem Sumimoto Chemicals Co Ltd, 1982
54 Jatrorrhizine Stem Sumimoto Chemicals Co Ltd, 1982
55 Berberine Stem Bisset and Nwaiwu, 1983
56 Salsolinol Stem Praman et al., 2012
57 (−)-Litcubinine Stem Praman et al., 2012
LIGNAN
58 Secoisolariciresinol Stem Chung, 2011
59 Syringaresinol Stem Chung, 2011
60 Adenosine Stem Praman et al., 2012
61 Uridine Stem Praman et al., 2012
62 Adenine Stem Praman et al., 2012
STEROL
63 β-sitosterol Stem Lin, 2009
64 Stigmasterol Stem Lin, 2009
65 Makisterone C Stem Lin, 2009
(Praman et al., 2012; Figure 6). Sterols like β-sitosterol (63),
stigmasterol (64) and makisterone C (65) have also been isolated
from T. crispa (Lin, 2009; Figure 6).
PHARMACOLOGICAL PROPERTIES
Anti-Inflammatory and Immunomodulatory
Activities
The crude ethanol extract of T. crispa together with other
fractions were investigated for potential anti-inflammatory
activity by evaluating their effect on expression of intracellular
cytokine in LPS stimulated murine macrophage cell line
RAW264.7 (murine macrophages from blood). T. crispa
crude extract and its isolated fractions stimulated RAW264.7
proliferation in a dose dependent way. T. crispa crude extract
at a dose of 25–800µg/mL expressively increased RAW264.7
proliferation (Table 3). The ethanol extract of T. crispa and its
fractions also improved intracellular expressions of cytokine,
INF-γ, IL-6, and IL-8. Among all the fractions tested, ethyl acetate
fraction was the most active which exhibited significant (P ≤
0.05) increase in the intracellular expressions of cytokines in
RAW264.7macrophages (Abood et al., 2014). This suggested that
the compounds which exhibited immunomodulatory activity
were soluble in ethyl acetate. Four active compounds, i.e.,
cordioside, quercetin, paullinic acid, and boldine were identified
by LC-MS analysis of the ethyl acetate fraction. However,
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TABLE 3 | Summary of the Pharmacological activities of Tinospora crispa.
Pharmacological
activity
Tested substance Model used Tested Dose Results Reference
Anti-inflammatory
activity
Aqueous, Methanol
stem extract
TNF-α induced inflammation
in Human umbilical vein
endothelial cells
HUVECs were incubated at
concentrations: 100-
200-400-600µg/mL
Both extracts showed inhibition
of signaling molecules ICAM-1,
VCAM-1, MCP-1, M-CSF, while
the secretion of NO was
increased
Kamarazaman et al.,
2012a
Methanol extract Carrageenan induced
inflammation (edema) in
Sprague-dawley rats
30, 100, and 300mg/kg
intraperitonial
The methanol extract
significantly inhibited the
development of edema
Hipol et al., 2012
Immunomodulatory
effect
Ethanol extract And
isolated fractions
Detemination of intracellular
cytokine in LPS stimulated
murine macrophage cell line
RAW264.7
25–1000µg/mL T. crispa crude extract and its
isolated fraction stimulate
RAW264.7 cell viability and
intracellular expressions of
cytokine,INF-γ, IL-6, and IL-8
Abood et al., 2014
Cytotoxic activity water, methanol and
chloroform whole
plant extract
MCF-7, MDA-MB-231, HeLa,
and 3T3 fibroblast cells
10–100µg/mL of each
extract
All extracts showed
dose-dependent antiproliferative
activity
Ibahim et al., 2011
Methanol stem
Extract
HL-60 leukemic cells, HepG2
hepatoma cells and Hep3B
hepatoma cells, containing
virus
Cells were incubated with
0.03- 1 mg/mL
concentarion range for 72
hrs
Inhibition was observed by
methanol stem extract with IC50
HL-60; 0.12 mg/mL
HepG2; 1.03 mg/mL
Hep3B; 0.16 mg/mL
Sinchaikul et al.,
2007
aqueous crude
extract of T. crispa
stem
MTT assays using human
cancer cell lines;
MCF-7
HeLa
Caov-3
HepG2
Cells were incubated with
10-200µg/mL concentarion
range for 72 h
MCF-7: 107µg/mL,
HeLa; 165µg/mL,
Caov-3;100µg/mL
HepG2;: 165µg/mL
Amom et al., 2008
Antioxidant water, methanol and
chloroform whole
plant extract
DPPH free radical scavenging
assay
10–100µg/mL Methanol extract significantly
increased percentage radical
scavenging activity with IC50
value 12µg/mL and percentage
radical activity increased to
100% which was similar to
vitamin
Ibahim et al., 2011
Methanol extract of
stem
DPPH free radical scavenging
activity
0.1–0.5mg/kg The methanolic extract showed
inhibition of DPPH with IC50
value 0.118 mg/mL
Zulkefli et al., 2013
Methanol extract of
stem
Metal chelating assay 0.0625–1 mg/mL The extract showed inhibition of
metal chelating
Zulkefli et al., 2013
Methanol extract of
stem
Reducing Power Assay 0.0625–1 mg/mL The extract showed antioxidant
effect by reducing ferric ion
(Fe3+) to ferrous ion (Fe2+)
Zulkefli et al., 2013
Antinociceptive
Activity
Ethanol extract of
stem
Hot plate method and Acid
acetic-induced writhes in
male Balb C mice
30, 100, and 300mg/kg
intraperitonial
The extract exhibited
antinoceceptive response,
significant reduction in acetic
acid induced writhing response
Sulaiman et al.,
2008
Antimalarial activity Methanol extract chloroquine-sensitive malaria
parasite (Plasmodium berghei
ANKA) infected ICR mice
model
20, 100, and 200mg/kg
intraperitonial
The extract exhibited antimalarial
activity in dose-dependent
manner
Niljan et al., 2014
methanol extract antiplasmodial activity method
based on growth of
Plasmodium falciparum
0.1–2.5 mg/mL 100% inhibition of parasite
growth observed at 72 h at 2.5
mg/mL
Najib Nik a Rahman
et al., 1999
(Continued)
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TABLE 3 | Continued
Pharmacological
activity
Tested substance Model used Tested Dose Results Reference
methanol extract Adult female ddy mice model
infected intraperitoneally with
parasitised red blood cells.
(Plasmodium berghei ANKA)
5mg/kg Intra peritonial The extract showed inhibitory
effect on parasite growth
Najib Nik a Rahman
et al., 1999
Aqueous extract Antiplasmodial activity method
based on the measurement of
growth of parasites. Species:
chloroquine-sensitive strain
Plasmodium falciparum
Plant extract IC50 25µg/mL Bertani et al., 2005
Aqueous extract Determine effect on
intraerythrocytic cycle and
intrahepatic cycle in
Plasmodium yoelii yoelii 17X
strain infected swiss female
mice model
110mg/kg oral The extract presented good
antimalarial activity, inhibited
more than 50% of the parasite
development at dose of
110mg/kg
Bertani et al., 2005
Hypoglycaemic
effect
Aqueous extract alloxan-diabetic male wistar
albino rats model
4 g/L extract dissolved in
drinking water
The extract treated diabetic
animals exhibited lower fasting
blood glucose levels and higher
serum insulin levels
Noor et al., 1989
95% ethanolic
extract
Normoglycemic and
alloxan-diabetic male
Sprague-dawley rats model
125, 250, and 500mg/kg
oral administration
The blood sugar level of diabetic
rats decreased after receiving the
extract
Anulukanapakorn
et al., 2012
n-butanol fraction,
Ether fraction,
Aqueous fraction
Normoglycemic and
alloxan-diabetic male
Sprague-dawley rats model
50, 150, and 450mg/kg
Oral administration
n-butanol fraction and aqueous
fraction of T. crispa exhibited
significant hypoglycemic effect in
alloxan-diabetic rats
Anulukanapakorn
et al., 2012
Two diterpenoids
borapetosides A and
C isolated from
ethanolic extract of
vines
Induced Type 1 and Type2
diabetic induced ICR mice.
Type 1 induced by ip injection
of streptozotocin and type 2
induced by fat-rich chow and
20% fructose-sweetened
water
5mg/kg Ip The borapetosides A-C showed
lowering of plasma glucose
levels in normal and
streptozotocin-induced type 1
diabetic mice. Borapetoside C
increased glucose utilization in
peripheral tissues and reduced
hepatic gluconeogenesis
Lam et al., 2012
Borapetol B Determine blood glucose and
plasma insulin in
normoglycemic Wistar and
type 2 diabetic Goto-Kakizaki
rats by an oral glucose
tolerance test
10 µg/100 g body weight Blood glucose level significantly
decreased and insulin level
increased in both borapetol B
treated normoglycemic Wistar
and type 2 diabetic
Goto-Kakizaki rats as compared
to the placebo group
Lokman et al., 2013
Borapetol B Insulin secretion using isolated
pancreatic islets by batch
incubation and perifusion
0.1, 1, and 10 µg/mL Borapetol B increased secretion
of insulin from isolated islets in a
dose-dependent manner
Lokman et al., 2013
4,13-dihydroxy-2,8,
9-trimethoxydibenzo
[a,g]quinolizin
Acetylcholinesterase (AChE)
Inhibitory Activity by using
Ellman’s colorimetric method
62.5–1000µg/mL Weak inhibition IC50:517.6 ±
5.3µM
dihydrodiscretamine 62.5–1000µg/mL Moderate inhibition IC50: 276.1
± 1.8µM
columbamine 62.5–1000µg/mL strongest AChE inhibition IC50:
48.1 ± 1.3µM
magnoflorine 62.5–1000µg/mL No inhibition
N-formylannonaine 62.5–1000µg/mL Moderate inhibition IC50: 415.3
± 2.7µM
(Continued)
Frontiers in Pharmacology | www.frontiersin.org 8 March 2016 | Volume 7 | Article 59
Ahmad et al. Phytochemical and Pharmacological Aspects of T. crispa
TABLE 3 | Continued
Pharmacological
activity
Tested substance Model used Tested Dose Results Reference
N-
formylnornuciferine
62.5–1000µg/mL Weak inhibition IC50: 564.6 ±
2.1µM
N-trans-
feruloyltyramine
62.5–1000µg/mL No inhibition
Antifilarial effects The aqueous extract
of dried stems
Microfilaricidal activity based
upon microfilarial motility
Worms: subperiodic Brugia
malayi
The aqueous extract of T. crispa
was found to exhibit
microfilaricidal activity which was
investigated based upon direct
observation of the microfilarial
Zaridah et al., 2001
Cardiovascular
activity
n-butanol stem
extract
Determine effect on blood
pressure and heart rate in
normal and reserpinized
(5mg/kg) female wistar rats
model
1–100mg/kg, i.v The extract modified the actions
of the human cardiovascular
system. In reserpinized rats, the
T. crispa extract had a dual
effect: reduction in hypotensive
activity, followed by a small
increase in blood pressure while
in normal rat a small decrease in
beginning followed by an
increase in heart rate
Praman et al., 2011
Active components
isolated,
higenamine,
tyramine, salsolinol
uridine, and
adenosine
Determine effect on blood
pressure and heart rate in
normal and reserpinized
(5mg/kg) female wistar rats
model
Salsinol 0.1–10mg/kg
Higenamine
(0.001–0.3mg/kg)
Tyramine (0.003–1mg/kg)
Adenosine
(0.003–0.3mg/kg)
Uridine (0.1–100mg/kg)
IV
Salsolinol, Adenosine decreased
mean arterial blood pressure,
and heart rate while Uridine
increased mean arterial blood
pressure and decreased heart
rate. Higenamine decreased
mean arterial blood pressure and
increased heart rate. Tyramine
increased mean arterial blood
pressure and heart rate in normal
rats
Praman et al., 2013
chromatography of ethyl acetate fraction to further isolate
and characterize the active constituents was not performed.
Besides, the active constituents should also be studied at a
molecular level to explore their mechanisms of action and role as
immunomodulators.
The activity of the aqueous extract of T. crispa stem on
nitric oxide (NO) production in LPS stimulated peritoneal
macrophages was studied by Yokozawa et al. (2000) using Griess
reagent method. The aqueous extract exhibited a dose-dependent
(from 5 to 250µg/mL) inhibition of NO production. Bioassay-
guided isolation of the aqueous extract showed that N-trans-
feruloyltyramine was the active constituent responsible for the
inhibition of NO and this inhibition was linked with reduced
levels of inducible NO synthase (iNOS) expression. (Yokozawa
et al., 2000, 2001).
The secretion of macrophage colony stimulating factor
(M-CSF), vascular cell adhesion molecule (VCAM-1), and
intracellular cell adhesion molecule (ICAM-1) in TNF-α
stimulated human umbilical vein endothelial cells (HUVECs)
was reduced by the aqueous and methanol extracts of T. crispa
stem (Kamarazaman et al., 2012a). These adhesion molecules
(ICAM-1, VCAM-1) and an inflammatory signaling molecule
(M-CSF) were reported to be up-regulated during an immune
response. The recruitment of leukocytes was dependent on
ICAM-1 and VCAM-1 (Kamarazaman et al., 2012a).
The effect of the aqueous and methanol extracts of T. crispa
on cell-mediated immune response was evaluated by foot pad
reaction. The development of edema was significantly inhibited
by the aqueous extract at doses of 50, 100, and 150mg/kg and
the results were equivalent to ibuprofen (Hipol et al., 2012). The
early and late phases of carrageenan-induced inflammation were
affected by the extract. Furthermore, oral administration of 50%
methanol extract of stem, at a dose of 10mg/kg also inhibited the
carrageenan-induced edema in rats as compared to control group
(Higashino et al., 1992). However, these results differ from those
reported by Aher and Kumar Wahi (2010) for the other plant
of the same genus (T. cardifolia). According to Aher and Kumar
Wahi (2010), the methanol extract of T. cardifolia increased the
foot pad thickness in rats, at a dose of 100mg/kg.
Apart from the above-mentioned reports, there is deficiency
of data to offer proofs for anti-inflammatory activity. Actually,
adequate studies have not been performed on the inflammatory
cells, proinflammatory cytokines, and proinflammatory enzymes
(PLA2, COX and LOX, PGE2). The assessment of the effect
of pure compounds and fractions on the activity and gene
expression of enzymes and cytokines involved in inflammation
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FIGURE 2 | Chemical structures of flavones and flavone glycosides isolated from Tinospora crispa.
might be beneficial. Likewise, reactive oxygen species including
superoxide anion, hydroxyl radical, hydrogen peroxide, and
singlet oxygen play a vital part in pathogenesis of inflammation.
It would be exciting to assess the effect on these reactive oxygen
species. Taking together these results, it is quite premature to
conclude regarding the anti-inflammatory activity of T. crispa.
Anticholinesterase Activity
The hydrolysis of acetylcholine to choline is catalyzed by
an enzyme acetylcholinesterase (AChE). The hydrolysis of
acetylcholine results in the end of nerve impulse transmission
at the cholinergic synapses. The quarternary alkaloids,
(4,13-dihydroxy-2,8,9-trimethoxydibenzo quinolizinium,
magnoflorine, columbamine, N-formylannonaine,
dihydrodiscretamine, N-formylnornuciferine, and N-trans-
feruloyltyramine) isolated from T. crispa were investigated as
inhibitors of AChE by using Ellman’s colorimetric method. The
isolated compounds showed different activity profiles. Among
all the compounds, columbamine displayed the strongest AChE
inhibitory activity with an IC50 value of 48.1µM which was
comparable to that of physostigmine (IC50 31.4µM; Yusoff
et al., 2014). A number of alkaloids isolated from medicinal
plants have been reported for their AChE inhibitory activity.
Alkaloids isolated from T. crispa should be evaluated for their
AChE inhibitory activity. The AChE inhibition has therapeutic
potential for treatment of parkinson’s and alzheimer’s diseases,
senile dementia, ataxia, and myasthenia gravis. Nevertheless, the
results presented in above-mentioned study are not sufficient
to draw a meaningful conclusion. Hence, more cutting-edge
and mechanistic studies are needed to better understand the
anticholinesterase activity.
Antibacterial and Antifilarial Activities
Aqueous, ethanol and chloroform extracts of T. crispa were
evaluated for their antimicrobial activity against some gram-
positive (Bacillus cereus, Staphylococcus aureus, Listeria
monoctogens, Streptococcus pneumonia, and Clostridium
diphtheria) and gram-negative bacteria (Shigella flexneri,
Salmonella typhi, Proteus vulgaris, Escherichia coli, and Klebsiella
pneumonia). The activity of L. monoctogens and P. vulgaris
was slightly inhibited by all the extracts. The ethanol extract
was effective against S. pneumonia, S. aureus, S. flexneri, and
C. diphtheria while chloroform extract inhibited the activities
of S. flexneri, C. diphtheria, and S. pneumonia. However, E.
coli, B. cereus, and S. typhi remained unaffected by all the
extracts (Zakaria et al., 2006). The above-presented results
do not coincide with the findings of Md and Mohammad
(2011) and Chittur and Gunjan (2012). According to Md
and Mohammad (2011), the chloroform extract of T. crispa
inhibited E. coli, B. cereus, and S. typhi with zone of inhibitions
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FIGURE 3 | Chemical structures of terpenoids obtained from Tinospora crispa.
of 7, 8, and 9mm, respectively. On the other hand, Chittur
and Gunjan (2012) reported that at a dose of 50µg/mL, the
aqueous and ethanol extracts of T. crispa inhibited E.coli
with zone of inhibition of 2.6 and 3.6mm, respectively. As
no dose-dependent study was performed, it is difficult to
evaluate the minimum inhibitory concentration (MIC) and the
minimum bactericidal concentration (MBC). The antibacterial
studies carried out by Al-alusi et al. (2010) have shown worth
mentioning antibacterial activity of T. crispa extracts against
the methicillin-resistant S. aureus (MRSA) as compared to the
control (vancomycin). The traditional use of T. crispa in the
treatment of cholera and syphilitic sores could be validated
by investigating its inhibitory effect on the activity of Vibrio
cholera and Treponema pallidum. The antibacterial activity of
T. crispa needs to be extensively studied and the mechanism
involved in the antibacterial activity should also be further
explored.
The aqueous extract of dried stems of T. crispa, investigated
for in vitro antifilarial effects, showed moderate activity against
the adult worms of sub periodic Brugia malayi whereby the
value of relative movability values were used as a measure
of the antifilarial activity (Zaridah et al., 2001). The aqueous
extract of T. crispa exhibited microfilaricidal activity which was
investigated based on direct observation of the microfilarial
motility (Merawin et al., 2010). The bioactive compounds
contributing to the antifilarial activity should be isolated and
further studies need to be carried to study their mechanisms of
action.
Antioxidant Activity
On the basis of DPPH, FRAP, and TBA tests, the aqueous crude
extract of T. crispa stem was found to display high antioxidant
activity and its antioxidative potency was equivalent to the
previously established antioxidants like BHT and vitamin C
(Amom et al., 2008; Zulkhairi et al., 2009). The antioxidant assay
performed by Froemming (2011) exhibited that the methanol
extract of T. crispa displayed the highest antioxidant activity
which was determined by measuring total flavonoid content,
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FIGURE 4 | Cisclerodane-type furanoditerpenoids isolated from Tinospora crispa.
total phenolic content, and DPPH free radical scavenging
activity. The antioxidant activity could be attributed to the
phenolic compounds present in T. crispa such as flavonoids
that act as free radical scavengers. Cavin et al. (1998) isolated
vanillin, syringin, N-formylannonain, N-formylnornuciferin,
borapetosides B, C, and F, N cis- feruloyltyramine, N-
trans-feruloyltyramine, and secoisolariciresinol from the
dichloromethane extract of T. crispa. Antioxidant and free-
radical scavenging potency of N-cis-feruloyltyramine, N-trans-
feruloyltyramine, and secoisolariciresinol were higher than
the synthetic antioxidant butylhydroxytoluene (BHT). The
antioxidant activity could be of therapeutic importance in
preventing oxidative stress involved in the development of
several diseases including cardiovascular and neurological
disorders.
Atherosclerosis Inhibitory Activity
Amom et al. (2011) discovered that the aqueous extract from
T. crispa stem administered to hypercholesterolemic rabbits
delayed the development of atherosclerosis by suppressing
the levels of total cholesterol, triglycerides and low density
lipoproteins. In contrast, the level of high density lipoproteins
was found to be significantly increased. Furthermore, they also
demonstrated that the aqueous andmethanol extracts of T. crispa
decreased the malondialdehyde level in a dose-dependent
manner by increasing the activity of antioxidant enzymes
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FIGURE 5 | Chemical structures of alkaloids present in Tinospora crispa.
(catalase, superoxide dismutase, and glutathione peroxidase)
in H2O2 induced HUVECs (Kamarazaman et al., 2012b).
These antioxidant enzymes have been reported to inhibit the
reactive oxygen species that actively oxidize the LDL in blood
and result in the development of atherosclerosis. The above-
mentioned studies do not provide comprehensive and sufficient
information. The range of the tested doses was very narrow
and no information about the positive control, EC50 and
IC50 have been provided. Hence, it is too early to conclude
about the antiatherosclerosis activity of T. crispa. However,
these findings showed that T. crispa possesses the potential
activity and could be explored further as an atherosclerosis
inhibitory drug.
Antiparasitic Activity
The methanol extract from the whole plant of T. crispa exhibited
100% inhibition of Plasmodium falciparum growth after 72 h
at a dose of 2.5 mg/mL (Najib Nik a Rahman et al., 1999).
The chloroquine-sensitive strain of P. falciparum w2 was also
inhibited by the aqueous extract of the plant (IC50 25µg/mL).
Bertani et al. (2005) studied the effect of aqueous extract on
intra erythrocytic and intra hepatic cycle. In this experiment,
Swiss female mice infected with P. yoelii 17X were used. At
a dose of 110mg/kg, the extract inhibited more than 50%
of the parasite development (Bertani et al., 2005). Recently,
Niljan et al. (2014) determined the antimalarial activity of
the methanol extact of T. crispa in ICR mice infected with
chloroquine-sensitive malaria parasite P. berghei ANKA. It was
discovered that the crude extract of T. crispa exhibited inhibitory
effect on the growth of plasmodium in a dose-dependent
way. Rungruang and Boonmars (2009) investigated the in vivo
antimalarial effect of the crude extract of T. crispa. The mice
administrated with a daily dose of 80mg/kg of the extract
exhibited promising inhibitory activity against the parasite,
P. yoelii. Though, only crude extracts of T. crispa have been
evaluated for its antimalarial activity and no mechanism of
action has been described, still these results are in favor of
the traditional use of T. crispa as an antimalarial agent. The
above- mentioned findings should motivate the researchers
to investigate the antiplasmodial activity of pure compounds
from T. crispa for further characterization of their antimalarial
activity.
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FIGURE 6 | Chemical structures of lignans, nucleosides and sterols found in Tinospora crispa.
Cytotoxic Activity
The cytotoxic activities of different extracts of T. crispa had been
studied. The cytotoxic activity of the aqueous crude extract of
T. crispa stem was assessed against various human cancer cell
lines likeMCF-7, HeLa (Henrietta Lacks), Caov-3 (Homo sapiens
ovary adenocarcinoma cell line), and HepG2. The cytotoxic effect
exerted by the aqueous extract of T. crispa stem was comparable
to cisplatin and tamoxifen, with IC50 values as follows: MCF-
7 (IC50: 107µg/mL), HeLa (IC50: 165µg/mL), Caov-3 (IC50:
100µg/mL), and HepG2 (IC50: 165µg/mL; Amom et al., 2008).
In another study, Froemming (2011) investigated the cytotoxic
effect of the methanol extract of T. crispa on MDA-MB-231
(human breast adenocarcinoma cell line) and MCF-7 cancer
cell lines. The methanol extract of T. crispa exhibited a dose-
dependent cytotoxic effect on MDA-MB-231 and MCF-7 cancer
cell lines with IC50 values of 44.8 and 33.8µg/mL, respectively.
Water, methanol and chloroform extracts of the whole plant
exhibited dose-dependent antiproliferative activity against MCF-
7, MDA-MB-231, HeLa, and 3T3 (swiss albino mouse embryo
fibroblast) cells lines (Ibahim et al., 2011). The growth of
human cancer cell lines including HL-60 (human promyelocytic
leukemia cells), HepG2 and virus infected Hep3B was inhibited
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by themethanol extract of T. crispa stem. Themethanol extract of
T. crispa exerted its effect in a dose- and time-dependent manner
(Sinchaikul et al., 2007).
Most of the Tinospora species studied have similar chemical
classes of isolates or same chemical constituents but their
reported pharmacological properties were different and some
showed opposite responses. Amom et al. (2008) investigated
the anti-proliferative activity of the aqueous crude extract of
T. crispa and found that the extract exhibited moderate anti-
proliferative activity on selected human cancer cell lines (IC50
MCF-7: 107µg/ml, HeLa: 165µg/ml, Caov-3: 100µg/ml, and
HepG2: 165µg/ml). While Jagetia et al. (1998) evaluated the
antineoplastic activity of Tinospora cordifolia in cultured HeLa
cells and found that exposure of HeLa cells to 0, 5, 10, 25, 50, and
100 mg/mL of the extracts (methanol, aqueous, and methylene
chloride) resulted in a dose-dependent but significant increase
in cell killing, when compared to non-drug-treated controls.
This effect of Tinospora cordifolia extracts was comparable or
better than doxorubicin treatment. These reported studies are
quite preliminary in nature and were only carried out in vitro
using different cancer cell lines. These results are currently
premature to address the antitumor potential of T. crispa. The
active constituents and underlying mechanisms responsible for
antitumor properties are still unknown and are needed to be
discovered. Moreover, future studies validating therapeutic effect
in in vivomodel are required.
Cardio-Protective Activity
T. crispa extracts and isolated active compounds showed effects
on cardiovascular system both in vitro and in vivo. A study
revealed that the crude alcohol extract from the stems of
T. crispa caused an increase in blood pressure with a reduction
in heart rate in anesthetized dogs (Mokkhasmit et al., 1971). A
study conducted on the n-butanol extract of T. crispa revealed
the presence of at least three different cardiovascular-active
components which exerted their effect through β2-adrenergic
receptors to cause a decrease in blood pressure, β1 and β2-
adrenergic receptors to cause an increase in heart rate, α-
adrenergic receptors to bring about an increase in blood pressure
and heart rate, and a nonadrenergic and noncholinergic pathway
to cause a decrease in MAP and heart rate (Praman et al., 2011,
2013). Bioassay guided fractionation of the n-butanol extract of
the stems of T. crispa led to isolation of five active compounds
namely adenosine, uridine, salsolinol, higenamine, and tyramine.
The compounds exhibited effect on the mechanisms of blood
pressure and heart rate in anesthetized, normal, and reserpinized
rats. Salsolinol and adenosine decreased mean arterial blood
pressure and heart rate, whereas uridine increased mean arterial
blood pressure and decreased heart rate. Higenamine decreased
mean arterial blood pressure and increased heart rate, moreover,
tyramine increased mean arterial blood pressure and heart rate
in normal rats. Salsolinol, tyramine, and higenamine acted via
the adrenoreceptors, while uridine and adenosine acted via the
purinergic adenosine A2 and P2 receptors to decrease blood
pressure with a transitory decrease of heart rate followed by
an increase. The crude extract of T. crispa along with the
isolated compounds exerted a positive ionotropic effect on the
rat isolated left atria stimulated with electrical field. Higenamine,
salsolinol (at low concentrations) and tyramine acted through
the adrenergic receptors to increase the force of the atrial
contraction, however a high concentration of salsolinol acted
secondarily by stimulating the release of acetylcholine. Adenosine
and uridine acted through the purinergic pathways to cause
negative ionotropic effects on the isolated left atria (Praman et al.,
2013). The two isolated triterpenes, namely, cycloeucalenol and
cycloeucalenone from the chloroform extract of the dried stems
of T. crispa. Both of the isolated triterpenes further indicatedmild
cardiotonic effects, where cycloeucalenol showed slight increase
in the right atrial contraction and initial reduction followed by
10% of sustained reduction on the left atria of the rat in vitro
meanwhile cycloeucalenone, showed slight change on the right
and left atrial contraction (Kongkathip et al., 2002). Imphanban
et al. (2009) isolated an aporphine alkaloid, namely (−)-N-
formylnornuciferine from the stems of T. crispa, which exhibited
in vitro cardiotonic activity. Synthesis of the mixture, (±)-N-
formylnornuciferine, by palladium-catalyzed coupling reaction,
showed significant reduction in the force of contraction and the
heart rate.
Antinociceptive Activity
The dried extract of the stem of T. crispa at a dose of 666mL
exhibited promising central analgesic activity (Almeida et al.,
2001). However, the number of tested doses is not sufficient
to highlight a dose-dependent effect. Owing to the lack of
tested doses and a negative control, it is difficult to draw a
conclusion from this study. Sulaiman et al. (2008) reported that
the ethanol extract of T. crispa reduced acetic acid-induced
writhes in mice in a dose-dependent manner. It was shown
that the ethanol extract at a dose of 300mg/kg exhibited higher
analgesic response (92%) than 100mg/kg of acetyl salicylic acid
(81%). Further investigations are needed to provide an evidence
for its traditional use against pain.
Cytochromes Inhibitory Activities
Cytochromes P450 (CYPs) are the principal enzymes that
catalyze the oxidative metabolism of drugs and other xenobiotics.
Isoforms of CYP such as CYP3A4, CYP2D6, CYP2C9, and
CYP2E1 have been reported to be involved in the metabolism.
The inhibition of CYP results in unexpected adverse drug
interactions due to changes in metabolic clearance of co-
administered drug. A radiometric assay carried out by Usia
et al. (2006a,b) against CYP3A4 and CYP2D6 revealed that
T. crispa exhibited an inhibitory activity over 70% on the
metabolism mediated by CYP3A4. To better understand the
inhibitory mechanism, N-methyl-14C]erythromycin and [O-
methyl- 14C]dextromethorphan were used as substrates in
human liver microsomes and the activity of CYP was determined
by measuring the production of 14C-formaldehyde. At a dose
of 0.5 mg/mL, T. crispa methanol extract exhibited more than
30% increase in CYP3A4 inhibition (Subehan et al., 2006). These
results suggest an inhibitory effect of T. crispa on CYP3A4 and
CYP2D6. The effect of T. crispa on other isomers of CYP viz
CYP2C9 and CYP2E1 also needs to be investigated to determine
the potential drug-drug interactions. Moreover, further work is
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needed to purify and identify active constituents responsible for
the inhibitory effect.
Antidiabetic Effect
The research undertaken by Noor and Ashcroft (1998) indicated
that the orally administrated extract of T. crispa displayed
significant antihyperglycaemic effect. The extract might comprise
of compounds which initiated the insulin secretion by the
modulation of β-cell Ca2+ concentration. Therefore, it can be
additionally used as an antidiabetic agent for the treatment
of type II diabetes. A potent in vitro insulinotropic activity
in the human and rat islets and HIT-T15 (syrian hamster
islet cells) B cells was observed after an oral administration
of T. crispa extract (Noor et al., 1989). Sriyapai et al. (2009)
studied the dry powder of T. crispa for hypoglycemic effect on
patients with metabolic syndrome. Twice daily administration
of 250mg T. crispa dry powder significantly decreased fasting
blood glucose from the baseline. Noipha and Ninla-Aesong,
2011) indicated that the extract of T. crispa enhanced glucose
uptake by in L6 myotubes which was linked to the increased
levels of GLUT1 transporter, AMPKα, and PPARγ transcript.
Likewise, among twelve furanoditerpenoids isolated from the
ethanol extract of T. crispa, borapetosides A, and borapetosides
C showed hypoglycemic effect in ICR diabetic mice. These
compounds reduced plasma glucose levels in normal and
streptozotocin-induced type-1 diabetic mice (Lam et al., 2012).
In addition bropetoside C increased glucose utilization in
peripheral tissues and decreased hepatic gluconeogenesis, thus
accounting for the hypoglycemic effect. Ruan et al (2012) studied
the molecular mechanism of borapetoside C for hypoglycemic
effects in normal and diabetic mice. The findings of the
study revealed that hypoglycemic effect of borapetoside C
was mediated via insulin receptor, protein kinase and glucose
transporter-2 pathway. They witnessed that borapetoside C
increased the glycogen level in skeletal muscle. Borapetoside
C increased the expression of glucose transporter-2 as well
as phosphorylation of insulin receptor and protein kinase B.
Borapetoside A increased the glycogen level in skeletal muscle
C2C12 and human hepatocellular carcinoma Hep3B cell lines
(Ruan et al, 2013). The report suggested that borapetoside A
exerted its hypoglycemic effect, primarily via augmentation of
glucose utilization of skeletal muscle and liver. Borapetoside A
exerted its hypoglycemic action by the stimulation of insulin
receptor, protein kinase and glucose transporter-2 pathway,
and the suppression of phosphoenolpyruvate carboxykinase
enzymes which regulate hepatic gluconeogenesis and glucolysis
(Pilkis and Granner, 1992). The borapetol B, isolated from the
methanol and water extracts of T. crispa stem showed anti-
diabetic activity in normoglycemic wistar and spontaneously type
2 diabetic Goto-Kakizaki rats. The blood glucose levels were
significantly decreased by borapetol B at a dose of 10 µg/100 g
in normoglycemic and in type 2 diabetic rats, while the insulin
level was significantly increased. Borapetol B dose-dependently
stimulated the secretion of insulin from pancreatic islets isolated
from rats without damaging islet beta cells (Lokman et al.,
2013). Taken together, these results support the traditional
use of T. crispa as an antidiabetic agent. Although T. crispa
extract and isolated pure compounds have exhibited antidiabetic
activity both in vitro and in vivo, the function in humans
is still unconvincing as humans were not involved in those
studies. Hence, T. crispa is worthwhile to be considered in
human diabetes treatment and, therefore, should be extensively
studied.
Clinical Trials
A randomized double blind placebo controlled trial was carried
out to investigate the efficacy of T. crispa as an additional
treatment in patients with type 2 diabetes mellitus who refused
insulin injection and did not respond to oral hypoglycemic drugs
(Sangsuwan et al., 2004). Twenty patients were apportioned
to receive T. crispa powder in capsule form at a dose of 1 g
thrice daily for 6 months. Twenty patients received a placebo.
The main results were alterations in glycosylated hemoglobin,
insulin, and fasting plasma glucose levels. The baseline features
of the patients in both groups were not considerably different.
There were no significant alterations in glycosylated hemoglobin,
insulin and fasting plasma glucose levels between the patients
within the group as well as between groups. Two patients who
received T. crispa exhibited noticeable rise of liver enzymes that
reverted to normal after withdrawing T. crispa. Furthermore,
patients in the T. crispa group had noteworthy weight decrease
and cholesterol elevation while taking T. crispa. It is hence
concluded that there is no proof to support the use of T. crispa
3 g a day for additional therapy in patients with type 2
diabetes mellitus that refused insulin injection and did not
respond to oral hypoglycemic drugs. The patients receiving
T. crispa might have a greater risk of hepatic dysfunction.
Currently, only one study related to antipyretic effect of
T. crispa could be found on http://www.clinicaltrials.gov/. In
this double blind, interventional, randomized, and placebo
controlled phase II trial, safety, acceptability and effectiveness
of T. crispa extract will be determined in patients with body
temperature 37.8–38.5◦C. The patients will receive 500mg of
T. crispa extract after every 4–6 h. Besides, the efficacy and safety
results of T. crispa extract will also be compared with those
of acetaminophen. Therefore, this interesting study may lead
to insightful development of knowledge regarding its clinical
efficacy. Nonetheless, more operationally thorough randomized
controlled trials are required.
TOXICOLOGY
Although several studies have assessed the pharmacological
properties of T. crispa, few data are available concerning its
toxicity. Chavalittumrong et al. (1997) carried out studies to
determine the acute and chronic toxicity of T. crispa. The acute
toxicity study revealed that the ethanol extract of T. crispa stem
did not cause any signs of toxicity or animal death at a dose of 4.0
g/kg of body weight (g/kg BW). However, the chronic toxicity
test for 6 months exhibited that administration of the ethanol
extract at a dose of 9.26 g/kg BW/day to rats caused hepatic
and renal toxicities. Histopathological examination revealed
higher frequency of bile duct proliferation and focal liver
cell hyperplasia. Significant rise in alkaline phosphatase (ALP),
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alanine aminotransferase (ALT) creatinine levels and relative
liver weights was also witnessed.
Kadir et al. (2011) reported that oral administration of the
ethanol extract of T. crispa at doses of 100 and 200mg/kg for 8
weeks potentiated the thioacetamide induced hepatotoxicity in
rats. Moreover, they reported that the ethanol extract of T. crispa
contained certain hepatotoxins which may be responsible for
this effect (Kadir et al., 2011). A human hepatotoxicity case
was reported due to chronic over use of herbal preparation of
T. crispa stem as a prophylactic agent against malaria (Denis et al.,
2007). Recently, Langrand et al. (2014) reported an incidence
of toxic hepatitis linked with chronic use of high doses of T.
crispa. They observed that a patient who received pellets of T.
crispa had problem of dark urine and pale stools, linked with
asthenia and right hypochondrial pain which lead to jaundice.
The histopathological results also confirmed a toxic reaction.
The herbal medicine was withdrawn on admission and the
patient completely recovered without treatment, with normal
liver function 2months after the acute episode. The data reported
about toxicity ofT. crispa are very limited, so toxicological aspects
of T. crispa need to be investigated comprehensively.
CONCLUSIONS AND FUTURE
DIRECTIONS
Herein, we documented the existing phytochemistry,
pharmacological properties, and application researches on
T. crispa. The amount of experimental data evidenced rich
nutrients and vast biological active substances in T. crispa. A
peruse of available scientific references show that the traditional
medical uses of T. crispa have been evaluated by modern
pharmacological studies. T. crispa has the potential multiple
pharmacological and therapeutic activities in the management
of hypertension, lumbago, postpartum remedy, tuberculosis,
hemorrhoids, wound healing, itching, muscle pain, etc., which
can be explained by the presence of various terpenoids, alkaloids,
lignans and nucleosides in the herb. The biological activities
and chemical nature of the bioactive compounds must be of
great attention for the researchers. Diterpenoid glycosides
from T. crispa have shown promising antidiabetic activity.
Further investigations on the terpenoids offer great potential
upon which they can be predicted to be successful clinical trial
candidates in antidiabetic therapy. Similarly, authentication of
all the secondary metabolites should be performed carefully
by advanced analytical techniques to approve the quality
and conforming biological activity. Most of the mentioned
pharmacological studies have provided some suggestive scientific
evidence for its various traditional uses in fever, internal
inflammation (Yokozawa et al., 2000, 2001; Kamarazaman
et al., 2012a), pain (Almeida et al., 2001; Sulaiman et al., 2008),
antibacterial (Zakaria et al., 2006; Chittur and Gunjan, 2012),
malaria (Niljan et al., 2014), diabetes (Lokman et al., 2013; Ruan
et al, 2013), and hypertension (Praman et al., 2011, 2013) as in
Asian countries, especially in Malaysia, Indonesia, Philippines,
China, Cambodia, and Bangladesh.
In a word, T. crispa has received much interest. However,
future studies are necessary to address issues regarding
composition of the extract, explicability of preclinical
experiments, and lack of transformation of the preclinical
results to clinical efficacy. As a result, T. crispa was still
employed as folk prescription and the related health products
are unpersuasive. Thereby, it is extremely important to conduct
detailed investigations on the composition and pharmacological
significance of medicinal plants and standardize the formulations
based on ingredients. Further systematic studies are necessary
to evaluate the efficacy using standardized extracts of T. crispa,
and to identify the bioactive molecules responsible for the
biological activities so that cost-effective, potential medicinal
drug and health products can be developed at a large scale.
Also, attempts should be made to conduct serious randomized
human trials and determine modes or mechanisms of action,
bioavailability, pharmacokinetics, and physiological pathways
for specific bioactives of T. crispa which might be responsible
behind the protective effects offered by extracts rich in flavonoids
and terpenoids in many pharmacological studies. As more
scientific evidences on therapeutic effects of T. crispa will be
found, products (e.g., health care products) based on it might
boom in the future.
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